miR-211 regulates the expression of RRM2 in tumoral metastasis and recurrence in colorectal cancer patients with a k-ras gene mutation

Chang,Chiu‑Chun; Lin,Chun‑Che; Wang,Chia‑Hung; Huang,Chi‑Chou; Ke,Tao‑Wei; Wei,Po‑Li; Yeh,Ken‑Tu; Hsu,Kai‑Cheng; Hsu,Nan‑Yung; Cheng,Ya‑Wen

doi:10.3892/ol.2018.8295

miR-211 regulates the expression of RRM2 in tumoral metastasis and recurrence in colorectal cancer patients with a k-ras gene mutation

Authors:
- Chiu‑Chun Chang
- Chun‑Che Lin
- Chia‑Hung Wang
- Chi‑Chou Huang
- Tao‑Wei Ke
- Po‑Li Wei
- Ken‑Tu Yeh
- Kai‑Cheng Hsu
- Nan‑Yung Hsu
- Ya‑Wen Cheng
View Affiliations

Affiliations: Institute of Medicine, College of Medicine, Chung Shan Medical University, Taichung 402, Taiwan, R.O.C., Department of Pharmacology, Tung's Taichung MetroHarbor Hospital, Taichung 435, Taiwan, R.O.C., School of Medicine, College of Medicine, Chung Shan Medical University, Taichung 402, Taiwan, R.O.C., Department of Surgery, Division of General Surgery, China Medical University Hospital, Taichung 402, Taiwan, R.O.C., Department of Surgery, Division of General Surgery, Taipei Medical University Hospital, Taipei Medical University, Taipei 115, Taiwan, R.O.C., Department of Pathology, Changhua Christian Hospital, Changhua 500, Taiwan, R.O.C., Cancer Center, Taipei Medical University Hospital, Taipei Medical University, Taipei 115, Taiwan, R.O.C.
Published online on: March 19, 2018 https://doi.org/10.3892/ol.2018.8295
Pages: 8107-8117

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer (CRC) ranks as the third‑leading cause of cancer‑associated mortalities in Taiwan. The expression of ribonucleotide reductase M2 (RRM2) and p53R2 is associated with tumoral malignancy and progression in several types of cancer. The aim of the present study was to determine the association of p53R2/RRM2 with the upstream expression of microRNA (miR)‑211 and the association of expression levels of p53, APC and k‑ras with clinical outcomes in patients with CRC. The study consisted of 192 tumor tissue samples obtained from patients with CRC. Immunohistochemistry and direct sequencing of DNA were performed to analyze p53R2/RRM2 protein expression and p53/APC/k‑ras gene mutations in these samples. The expression level of miR‑211 was detected by reverse transcription-quantitative polymerase chain reaction. The results showed that the expression of p53R2 was lower and that of RRM2 was higher in patients with lymph node metastasis, distant metastasis, and late‑stage CRC compared with patients without lymph node metastasis, distant metastasis and early‑stage CRC. A high expression of RRM2 in patients had a negative effect on overall survival (OS) and disease‑free survival (DFS) in CRC. Positive expression of RRM2 was detected in tumor tissues, and expression associated with the presence of k‑ras gene mutation. Furthermore, it was detected that the upstream miR‑211 expression was negatively associated with RRM2 expression in tumor tissues of patients with CRC. miR‑211 expression was associated with survival and tumoral recurrence in patients with k‑ras mutations. The present authors suggest that the downregulation of miR‑211 and overexpression of RRM2 in tumor tissues of patients with CRC could be used to predict metastases and disease prognosis, particularly in patients with k-ras gene mutations.

View Figures

View References

1	Su SY, Huang JY, Jian ZH, Ho CC, Lung CC and Liaw YP: Mortality of colorectal cancer in Taiwan, 1971–2010: Temporal changes and age-period-cohort analysis. Int J Colorectal Dis. 27:1665–1672. 2012. View Article : Google Scholar : PubMed/NCBI
2	Taiwan Cancer Registry. http://tcr.cph.ntu.edu.tw/main.php?Page=N1
3	Chiang CJ, Lo WC, Yang YW, You SL, Chen CJ and Lai MS: Incidence and survival of adult cancer patients in Taiwan, 2002–2012. J Formos Med Assoc. 115:1076–1088. 2016. View Article : Google Scholar : PubMed/NCBI
4	Chen TH, Chang SW, Huang CC, Wang KL, Yeh KT, Liu CN, Lee H, Lin CC and Cheng YW: The prognostic significance of APC gene mutation and miR-21 expression in advanced-stage colorectal cancer. Colorectal Dis. 15:1367–1374.. 2013. View Article : Google Scholar : PubMed/NCBI
5	Fodde R, Smits R and Clevers H: APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer. 1:55–67. 2001. View Article : Google Scholar : PubMed/NCBI
6	Reichard P: Ribonucleotide reductases: The evolution of allosteric regulation. Arch Biochem Biophy. 397:149–155. 2002. View Article : Google Scholar
7	Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y and Nakamura Y: Ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature. 404:42–49. 2000. View Article : Google Scholar : PubMed/NCBI
8	Fan H, Villegas C and Wright JA: Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential. Proc Natl Acad Sci USA. 93:14036–14040. 1996. View Article : Google Scholar : PubMed/NCBI
9	Liu X, Zhou B, Xue L, Shih J, Tye K, Lin W, Qi C, Chu P, Un F, Wen W and Yen Y: Metastasis-suppressing potential of ribonucleotide reductase small subunit p53R2 in human cancer cells. Clin Cancer Res. 12:6337–6344. 2006. View Article : Google Scholar : PubMed/NCBI
10	Liu X, Zhang H, Lai L, Wang X, Loera S, Xue L, He H, Zhang K, Hu S, Huang Y, et al: Ribouncleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers. Clin Sci (Lond). 124:567–578. 2013. View Article : Google Scholar : PubMed/NCBI
11	Cerqueira NM, Pereira S, Fernandes PA and Ramos MJ: Overview of ribonucleotide reductase inhibitors: An appealing target in anti-tumour therapy. Curr Med Chem. 12:1283–1294. 2005. View Article : Google Scholar : PubMed/NCBI
12	Slack FJ and Weidhaas JB: MicroRNA in cancer prognosis. N Engl J Med. 359:2720–2722. 2008. View Article : Google Scholar : PubMed/NCBI
13	Ke TW, Hsu HL, Wu YH, Chen WT, Cheng YW and Cheng CW: MicroRNA-224 suppresses colorectal cancer cell migration by targeting Cdc42. Dis Markers. 2014:6171502014. View Article : Google Scholar : PubMed/NCBI
14	Liu TP, Huang CC, Yeh KT, Ke TW, Wei PL and Cheng YW: Down-regulation of let-7a-5p predicts lymph node metastasis and prognosis impact on chemotherapy of colorectal cancer. Surg Oncol. 25:429–434. 2016. View Article : Google Scholar : PubMed/NCBI
15	Chen X and Qin Z: Post-transcriptional regulation by microRNA-21 and let-7a microRNA in paediatric cholesteatoma. J Int Med Res. 39:2110–2118. 2011. View Article : Google Scholar : PubMed/NCBI
16	Pfeffer SR, Yang CH and Pfeffer LM: The role of miR-21 in cancer. Drug Dev Res. 76:270–277. 2015. View Article : Google Scholar : PubMed/NCBI
17	Zhang F and Cheong JK: The renewed battle against RAS-mutant cancers. Cell Mol Life Sci. 73:1845–1858. 2016. View Article : Google Scholar : PubMed/NCBI
18	Rui YY, Zhang D, Zhou ZG, Wang C, Yang L, Yu YY and Chen HN: Can K-ras Gene mutation be utilized as prognostic biomarker for colorectal cancer patients receiving chemotherapy? A meta-analysis and systematic review. PLoS One. 8:e779012013. View Article : Google Scholar : PubMed/NCBI
19	Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E and Ciardiello F: Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol. 6:519–527. 2009. View Article : Google Scholar : PubMed/NCBI
20	Yoshida Y, Tsunoda T, Doi K, Tanaka Y, Fujimoto T, Machida T, Ota T, Koyanagi M, Takashima Y, Sasazuki T, et al: KRAS-mediated up-regulation of RRM2 expression is essential for the proliferation of colorectal cancer cell lines. Anticancer Res. 31:2535–2539. 2011.PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Hsu NY, Wu JY, Liu X, Yen Y, Chen CY, Chou MC, Lin CH, Lee H and Cheng YW: Expression status of ribonucleotide reductase small subunits hRRM2/p53R2 as prognostic biomarkers in stage i and ii non-small cell lung cancer. Anticancer Res. 31:3475–3481. 2011.PubMed/NCBI
23	Chen IC, Lee KH, Hsu YH, Wang WR, Chen CM and Cheng YW: Expression pattern and clinicopathological relevance of the indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase protein in colorectal cancer. Dis Markers. 2016:81697242016. View Article : Google Scholar : PubMed/NCBI
24	Huang Y, Liu X, Wang YH, Yeh SD, Chen CL, Nelson RA, Chu P, Wilson T and Yen Y: The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers. Urol Oncol. 32:51.e9–e19. 2014. View Article : Google Scholar
25	Wei CH, Gorgan TR, Elashoff DA, Hines OJ, Farrell JJ and Donahue TR: A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers. Pancreas. 42:1303–1310. 2013. View Article : Google Scholar : PubMed/NCBI
26	Wang L, Huang J and Jiang M: RRM2 computational phosphoprotein network construction and analysis between no-tumor hepatitis/cirrhotic liver tissues and human hepatocellular carcinoma (HCC). Cell Physiol Biochem. 26:303–310. 2010. View Article : Google Scholar : PubMed/NCBI
27	Maftouh M, Avan A, Funel N, Frampton AE, Fiuji H, Pelliccioni S, Castellano L, Galla V, Peters GJ and Giovannetti E: miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells. Nucleosides Nucleotides Nucleic Acids. 33:384–393. 2014. View Article : Google Scholar : PubMed/NCBI
28	Zhong Z, Cao Y, Yang S and Zhang S: Overexpression of RRM2 in gastric cancer cell promotes their invasiveness via AKT/NF-κB signaling pathway. Pharmazie. 71:280–284. 2016.PubMed/NCBI
29	Fang Z, Gong C, Liu H, Zhang X, Mei L, Song M, Qiu L, Luo S, Zhu Z, Zhang R, et al: E2F1 promote the aggressiveness of human colorectal cancer by activating the ribonucleotide reductase small subunit M2. Biochem Biophys Res Commun. 464:407–415. 2015. View Article : Google Scholar : PubMed/NCBI
30	Zhou BS, Tsai P, Ker R, Tsai J, Ho R, Yu J, Shih J and Yen Y: Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin Exp Metastasis. 16:43–49. 1998. View Article : Google Scholar : PubMed/NCBI
31	Duxbury MS and Whang EE: RRM2 induces NF-kB-dependent MMP-9 activation and enhances cellular invasiveness. Biochem Biophys Res Commun. 354:190–196. 2007. View Article : Google Scholar : PubMed/NCBI
32	Tiwari P, Sahay S, Pandey M, Qadri SS and Gupta KP: Preventive effects of butyric acid, nicotinamide, calcium glucarate alone or in combination during the 7, 12-dimethylbenz anthracene induced mouse skin tumorigenesis via modulation of K-Ras-PI3K-AKTpathway and associated micro RNAs. Biochimie. 121:112–122. 2016. View Article : Google Scholar : PubMed/NCBI
33	Ren J, Li G, Ge J, Li X and Zhao Y: Is K-ras gene mutation a prognostic factor for colorectal cancer: A systematic review and meta-analysis. Dis Colon Rectum. 55:913–923. 2012. View Article : Google Scholar : PubMed/NCBI
34	Bazan V, Migliavacca M, Zanna I, Tubiolo C, Grassi N, Latteri MA, La Farina M, Albanese I, Dardanoni G, Salerno S, et al: Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol. 13:1438–1446. 2002. View Article : Google Scholar : PubMed/NCBI
35	Conlin A, Smith G, Carey FA, Wolf CR and Steele RJ: The prognostic significance of K-ras, p53 and APC mutations in colorectal carcinoma. Gut. 54:1283–1286. 2005. View Article : Google Scholar : PubMed/NCBI
36	Pricolo VE, Finkelstein SD, Wu TT, Keller G, Bakker A, Swalsky PA and Bland KI: Prognostic value of TP53 and K-ras-2 mutational analysis in stage III carcinoma of the colon. Am J Surg. 171:41–46. 1996. View Article : Google Scholar : PubMed/NCBI
37	Andersen SN, Lovig T, Breivik J, Lund E, Gaudernack G, Meling GI and Rognum TO: K-ras mutations and prognosis in large-bowel carcinomas. Scand J Gastroenterol. 32:62–69. 1997. View Article : Google Scholar : PubMed/NCBI